The LACOG-0415 phase II trial: abiraterone acetate and ADT versus apalutamide versus abiraterone acetate and apalutamide in patients with advanced prostate cancer with non-castration testosterone levels

BACKGROUND: Testosterone suppression is the standard treatment for advanced prostate cancer, and it is associated with side-effects that impair patients’ quality of life, like sexual dysfunction, osteoporosis, weight gain, and increased cardiovascular risk. We hypothesized that abiraterone acetate w...

詳細記述

保存先:
書誌詳細
出版年:BMC Cancer
主要な著者: Werutsky, Gustavo, Maluf, Fernando Cotait, Cronemberger, Eduardo Henrique, Carrera Souza, Vinicius, dos Santos Martins, Suelen Patricia, Peixoto, Fábio, Smaletz, Oren, Schutz, Fábio, Herchenhorn, Daniel, Santos, Telma, Mavignier Carcano, Flavio, Queiroz Muniz, David, Nunes Filho, Paulo R. S., Zaffaroni, Facundo, Barrios, Carlos, Fay, André
フォーマット: Artigo
言語:Inglês
出版事項: BioMed Central 2019
主題:
Study Protocol
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC6533731/
https://ncbi.nlm.nih.gov/pubmed/31122212
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-019-5709-y
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料